Merck Profit, Revenue Beat; Raises Full-Year Earnings Guidance
This article is for subscribers only.
Merck & Co. reported third-quarter adjusted earnings of $1.74 per share and revenue of $12.55 billion, both of which beat analyst expectations. Sales for its blockbuster cancer drug Keytruda also came in above analyst projections.
The company also released updated 2020 guidance, with upbeat profit expectations for the year.